Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Ivy K HughesDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118.ORCID 0000-0002-8769-4011
Siarhei KharytonchykDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109.ORCID 0000-0001-7031-8135
Sita RamaswamyDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118.ORCID 0000-0003-1479-6954
Sallieu JallohDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118.
James B HoodDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118.
Xianbao HeDepartment of Medicine, Section of Infectious Diseases, Boston Medical Center, Boston, MA 02118.ORCID 0000-0003-2448-8437
Andrew J HendersonDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118.ORCID 0000-0002-9299-5302
Hisashi AkiyamaDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118.
Alice TelesnitskyDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109.ORCID 0000-0001-9878-5931
Suryaram GummuluruDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118.ORCID 0000-0002-8606-8481
Funding
Center for Structural Biology of HIV RNAU54AI170660 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALICE TELESNITSKY · 2022 to 2026
$32.1M
Persistent HIV-1 expression and microglia dysfunctionR01DA055488 · NIDA · BOSTON MEDICAL CENTER · PI GUMMULURU, SURYARAM, HENDERSON, ANDREW J · 2021 to 2025
$3.7M
Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by Opiates and HIV InfectionR01DA051889 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CHENG, CHRISTINE, GUMMULURU, SURYARAM · 2020 to 2024
$3.5M
RNA modification and innate immune activation in HIV infectionR01AI183400 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Hisashi Akiyama · 2024 to 2026
$2.5M
Defective HIV proviruses and Persistent Innate Immune ActivationR01AI187175 · NIAID · BOSTON MEDICAL CENTER · PI SURYARAM GUMMULURU, Andrew J Henderson · 2024 to 2026
$2.4M
Mechanisms of Persistent Inflammasome Activation in Myeloid CellsR01DA059952 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SURYARAM GUMMULURU, Andrew J Henderson · 2024 to 2026
$2.3M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 5P30AI042853HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI183400HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI187175HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI50498HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U54AI170660HHS | NIH | National Institute on Drug Abuse (NIDA) R01DA051889HHS | NIH | National Institute on Drug Abuse (NIDA) R01DA055488HHS | NIH | National Institute on Drug Abuse (NIDA) R01DA059952
6 · The paper itself
Abstract
Heterogenous transcription start site (TSS) usage dictates the 5' leader structure and function of unspliced HIV-1 RNAs (usRNA). We and others have previously reported that expression and Rev/CRM1-mediated nuclear export of HIV-1 usRNA in macrophages activates MDA5, MAVS, and innate immune signaling cascades. In this study, we reveal that MDA5 sensing of viral usRNA is largely determined by TSS and cytoplasmic RNA function in macrophages. We show that HIV-1 usRNAs (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Transcription start site heterogeneity controls MDA5 sensing of unspliced HIV-1 RNAs. · full record | OpenQuestion